A Randomized Trial of AM0010 in Combination with Nivolumab vs Nivolumab Alone as Second Line Therapy in Subjects with Stage IV Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (17201) (Cypress2)

A Randomized Trial of AM0010 in Combination with Nivolumab vs Nivolumab Alone as Second Line Therapy in Subjects with Stage IV Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (17201) (Cypress2)

Trial Category:
Lung
Phase
II
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE
Nebraska Hematology Oncology, Lincoln, NE

This study is looking at the drug AM0010 in combination with Nivolumab versus Nivolumab alone in patients with advanced lung cancer whose tumor has certain markers that affect immune response.  Patients are "randomized" on this study.  This means a computer tells the study team which treatment you will receive.  Neither the patient or the physician can choose the treatment assignment.  The purpose of Randomized trials is to equally study both treatment options using the same criteria in order to identify if one treatment may be superior to another treatment. 

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members